Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 3, 2025
Reporting Period: The filing announces the submission of the Annual Report and Form 20-F for the year ended December 31, 2024.
Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company focuses on commercializing and developing a portfolio of innovative medicines, including small molecules and biologics, for patients with rare, debilitating, and life-threatening diseases. Operations span over 30 markets globally.
Key Financial Metrics
The provided text is a press release announcing the filing of the 2024 Annual Report and Form 20-F. It does not contain specific financial data.
- Revenue: Not provided in this filing.
- Profit/Loss: Not provided in this filing.
- Cash Flow: Not provided in this filing.
- Margins: Not provided in this filing.
- Debt and Liquidity: Not provided in this filing.
Investors must refer to the full 2024 Annual Report and Form 20-F, available on the company's website or the SEC website, for detailed financial statements.
Material Changes
The filing text does not provide specific comparative financial data or details regarding material changes versus the prior comparable period. It serves solely as a notification of the availability of the annual financial documents.
Guidance, Outlook, and Risks
Management Commentary: The company reiterates its dedication to transforming the lives of patients with rare diseases through its portfolio of small molecules and biologics.
Guidance and Outlook: No specific financial guidance or operational outlook is included in this announcement.
Risks and Contingencies: The press release notes that the information qualifies as inside information under Article 7(1) of the EU Market Abuse Regulation. No specific risk factors or contingencies are detailed in this text.
Key Facts for Investor Verification
- Verify the full 2024 Annual Report and Form 20-F on the Pharming Group investor relations website or the SEC EDGAR database for actual financial performance.
- Confirm the company's operational status across its 30+ global markets as described in the full annual report.
- Review the detailed risk factors and management discussion and analysis (MD&A) sections within the filed Form 20-F.
- Note the filing date of April 3, 2025, for the 2024 fiscal year results.